Ollin Biosciences Acquisition: What Is J&J Paying and What Does It Get?

Nov 17, 2026 | Biotech

Image Source: Generated by Google Gemini
Written by: LSDN Editorial Team
On behalf of: Life Science Daily News

Johnson & Johnson (J&J) will pay $2.2 billion upfront in the Ollin Biosciences acquisition. Up to about $1.125 billion more is payable in milestones. The deal brings OLN324, a bispecific antibody for wet age-related macular degeneration (AMD) and diabetic macular oedema (DME). J&J announced the definitive agreement to acquire Ollin on 16 November 2026. The deal has not closed. J&J expects completion before the end of 2026, subject to regulatory approvals and customary conditions.

Deal terms at a glance

Buyer Johnson & Johnson (NYSE: JNJ)
Target Ollin Biosciences, Inc. (private)
Asset OLN324, VEGF and Ang2 bispecific antibody
Upfront $2.2 billion
Milestones Up to approximately $1.125 billion, regulatory and commercial
Royalties or CVR None stated in the release
Total announced value Not stated; upfront and milestones sum to about $3.325 billion
Separate funding Blackstone Life Sciences to pay J&J $750 million over multiple years for Phase 3, contingent on close
Expected close Before the end of 2026
Status Definitive agreement signed, not completed, as at 16 November 2026

How much is J&J paying in the Ollin Biosciences acquisition?

Upfront and milestones

J&J’s release sets out two components. The first is a $2.2 billion upfront payment. The second is regulatory and commercial milestones of up to approximately $1.125 billion. The release does not state a total deal value.

Added together, the two components come to about $3.325 billion. That sum is a ceiling, not the price paid. Milestones fall due only if OLN324 reaches the events they are tied to. The release does not say what those events are. It names no royalties to Ollin’s holders and no contingent value rights. It names no financial or legal advisers either.

How the figures were reported

The deal had been trailed the day before. Investing.com, summarising a Financial Times report on 15 November, said talks valued Ollin at up to $3.4 billion. That report described a possible $2.2 billion upfront and up to $1.2 billion in milestones. The figures here follow J&J’s release.

What is the Blackstone funding agreement?

J&J will also enter a separate development funding agreement with Blackstone Life Sciences. Blackstone will pay J&J a total of $750 million over multiple years. According to the release, the money is meant to fully fund Phase 3 development of OLN324.

In return, Blackstone becomes eligible for certain regulatory and sales milestone payments. It will also receive single-digit royalties. The release does not give the milestone amounts. The agreement is contingent on the acquisition closing.

The $750 million is not part of the price in the Ollin Biosciences acquisition. It flows the other way, from Blackstone to J&J. In exchange, Blackstone takes a share of any future returns from OLN324. This shifts part of the late-stage development risk away from J&J.

What does J&J get from Ollin?

OLN324 and its stage

OLN324 is an investigational bispecific antibody. It targets vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2). The release describes high Ang2 potency in a small protein format, which it calls a minibody. J&J describes OLN324 as a Phase 3 candidate. The release says wet AMD and DME together affect more than 40 million people worldwide.

In June 2026, Ollin said it had completed an End-of-Phase 2 meeting with the FDA. It also said it had received scientific advice from the European Medicines Agency. At that point it planned global Phase 3 studies starting in the second half of 2026. Four Phase 3 OLN324 studies are registered, two per indication. When last updated, the wet AMD study MOJAVE and the DME study GOBI were listed as not yet recruiting.

The JADE data

The main clinical data come from JADE, a randomised Phase 1b study in the US. It compared OLN324 at 2 mg and 4 mg with faricimab 6 mg. Ollin reported 164 enrolled patients with DME or wet AMD. Safety and tolerability formed the primary objective. Efficacy measures were prespecified exploratory endpoints.

Ollin released final Week 20 JADE data on 30 March 2026. In DME, it reported greater retinal drying with OLN324 than with faricimab. In wet AMD, it reported comparable drying through Week 12, sustained to Week 20. The 4 mg dose showed a 2.2 letter visual acuity advantage at Week 20 in wet AMD.

The release gave no confidence intervals or p-values for these comparisons. Ollin reported no intraocular inflammation with OLN324, against one case with faricimab. JADE was small and exploratory, so its comparisons are not conclusive. Phase 3 results will be needed to test them. A separate article looks at how OLN324 compares with Vabysmo in more detail.

Who holds what after the Ollin Biosciences acquisition

On completion, J&J will own Ollin outright. OLN324 was discovered by Innovent Biologics, which has co-developed it with Ollin. Innovent’s own code for the molecule is IBI324. J&J’s release does not mention Innovent or China.

The split of territorial rights between Ollin and Innovent has not been disclosed. No territory terms had been published as at 16 November 2026. Innovent’s June release said the global Phase 3 programme would include China and South Korea through the Innovent partnership.

Ollin also has a second programme, OLN102. It is a TSHR and IGF-1R bispecific antibody for thyroid eye disease, discovered by VelaVigo. J&J’s release does not mention OLN102.

Why is J&J buying Ollin?

J&J’s stated rationale centres on the profile of OLN324. Kip Connor, Vice President, Ophthalmology Disease Area Stronghold Leader, Johnson & Johnson, gave the company’s view. He said OLN324 “selectively targets two important drivers of retinal disease.” He added that it could achieve stronger and more sustained disease control.

These are company statements about an unapproved medicine. J&J also says the deal would strengthen its position in ophthalmology. Neither claim has yet been tested in a Phase 3 trial.

The comparator matters. Roche’s Vabysmo (faricimab) already targets VEGF and Ang2. The FDA approved Vabysmo for wet AMD and DME in January 2022, according to Roche. OLN324 would therefore enter an established class, not create a new one. Its case rests on outperforming faricimab, which JADE tested only at small scale. At least one Phase 3 study uses aflibercept, not faricimab, as its comparator.

When will the Ollin Biosciences acquisition close?

J&J expects the transaction to close before the end of 2026. Closing depends on applicable regulatory approvals and customary closing conditions. The release does not name the specific approvals required.

Ollin is privately held, so the deal involves no public tender offer. J&J says it will disclose the accounting treatment on or before closing. Until then, Ollin remains an independent company. The Blackstone agreement takes effect only if the acquisition completes.

How the deal fits the 2026 biotech M&A market

The Ollin Biosciences acquisition lands in a busy year for biotech M&A. According to Investing.com’s summary, the Financial Times, citing Stifel, reported 46 sales of biotechs valued above $1 billion in 2026. That would exceed the previous annual record of 35.

Earlier large transactions are listed in the 2026 biotech M&A tracker. This deal will be added at its next monthly update. Retinal disease has also drawn other pipeline activity this year, including a Merck candidate in diabetic macular oedema.

What to watch next

The first marker is completion, which J&J guides for before the end of 2026. Any regulatory clearance disclosed along the way would confirm progress. J&J’s accounting treatment is also due on or before closing.

After that, the focus moves to the Phase 3 programme under J&J ownership. Trial starts, enrolment and readout timing will show how fast OLN324 can move. Any disclosure of Innovent’s rights or economics would clarify who benefits from success.

The milestones will matter too. J&J has not said what triggers them. Until it does, the extra $1.125 billion remains a contingent figure, not money paid. For now, the Ollin Biosciences acquisition is a $2.2 billion upfront bet on improving the VEGF and Ang2 class.

    References:
    1. Johnson & Johnson, 2026. Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology (Business Wire, 16 November 2026). https://www.businesswire.com/news/home/20261116907414/en
    2. Ollin Biosciences, 2026. Ollin Biosciences announces final data from randomized head-to-head study of OLN324 compared to faricimab (Vabysmo) in wet AMD and DME (Business Wire via BioSpace, 30 March 2026). https://www.biospace.com/press-releases/ollin-biosciences-announces-final-data-from-randomized-head-to-head-study-of-oln324-compared-to-faricimab-vabysmo-in-wet-age-related-macular-degeneration-and-diabetic-macular-edema
    3. Ollin Biosciences, 2025. Ollin Biosciences launches with mission to accelerate best-in-class therapies in ophthalmology (Business Wire, 16 September 2025). https://www.businesswire.com/news/home/20250916836730/en
    4. Roche, 2022. FDA approves Roche’s Vabysmo, the first bispecific antibody for the eye, to treat two leading causes of vision loss (31 January 2022). https://www.roche.com/media/releases/med-cor-2022-01-31
    All content is published for informational purposes only and does not constitute medical, legal, or investment advice. For more information, see our Terms and Conditions.

    Articles that may be of interest

    Articles that may be of interest